Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma

To evaluate the safety, maximum-tolerated dose (MTD), pharmacokinetics, and antitumor activity of dacetuzumab in patients with refractory or recurrent B-cell non-Hodgkin's lymphoma (NHL). In this open-label, dose-escalation phase I study, dacetuzumab was administered to six cohorts of adult pat...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of clinical oncology Vol. 27; no. 26; p. 4371
Main Authors:	Advani, Ranjana, Forero-Torres, Andres, Furman, Richard R, Rosenblatt, Joseph D, Younes, Anas, Ren, Hong, Harrop, Kate, Whiting, Nancy, Drachman, Jonathan G
Format:	Journal Article
Language:	English
Published:	United States 10.09.2009
Subjects:	Adult Aged Aged, 80 and over Anemia - chemically induced Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - pharmacokinetics Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized CD40 Antigens - immunology Cohort Studies Cytokines - blood Dose-Response Relationship, Drug Drug Resistance, Neoplasm Fatigue - chemically induced Female Fever - chemically induced Headache - chemically induced Humans Lymphoma, B-Cell - drug therapy Lymphoma, B-Cell - metabolism Lymphoma, Non-Hodgkin - drug therapy Lymphoma, Non-Hodgkin - metabolism Male Middle Aged Recurrence Treatment Outcome Young Adult
ISSN:	1527-7755, 1527-7755
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!